Portal de Periódicos da CAPES

Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials

2015; Elsevier BV; Volume: 20; Issue: 12 Linguagem: Inglês

10.1016/j.drudis.2015.08.005

1878-5832

David M. Hyman, David B. Solit, Maria E. Arcila, Donavan T. Cheng, Paul Sabbatini, José Baselga, Michael F. Berger, Marc Ladanyi,

Colorectal Cancer Treatments and Studies

Implementing a center-wide precision medicine strategy at a major cancer center is a true multidisciplinary effort and requires comprehensive alignment of a broad screening strategy with a clinical research enterprise that can use these data to accelerate development of new treatments. Here, we describe the genomic screening approach at Memorial Sloan Kettering Cancer Center, a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology designated MSK-IMPACT, and how it enables and supports a large clinical trial portfolio enriched for multi-histology, biomarker-selected, 'basket' studies of targeted therapies.